MIRA
INFORM REPORT
|
Report Date : |
10.01.2007 |
IDENTIFICATION
DETAILS
|
Name : |
BHAWANISHANKAR
COMPANY |
|
|
|
|
Registered Office : |
25,
Kavi Nirav Lane, 3rd Floor, Zhaveri Bazar, Mumbai-400002,
Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
1982 |
|
|
|
|
Legal Form : |
Sole
Proprietory Concern |
|
|
|
|
Line of Business : |
Trader
of Pharmaceuticals, Formulations, Tablets and Capsules |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD
130000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject
is a well established concern having satisfactory track. Mr.
Pradip Lohia assured to provide financials and if he provides, we shall
permit to you. Trade relations
are fair. Payments are usually correct and as per commitments. The
concern can be considered good for normal business dealings at usual trade
terms and conditions. |
LOCATIONS
|
Registered Office : |
25,
Kavi Nirav Lane, 3rd Floor, Zhaveri Bazar, Mumbai-400002,
Maharashtra, India |
|
Tel. No.: |
91-22-22404256/
22400391 |
|
Mobile No.: |
91-9820127205 |
|
Fax No.: |
91-22-22418272 |
|
E-Mail : |
|
|
Area : |
300
Sq.ft. |
|
Location : |
Owned |
SOLE PROPRIETOR
|
Name : |
Mr.
Pradip Lohia |
|
Designation : |
Proprietor |
|
Date of Birth/Age : |
47
years |
|
Experience : |
25
years |
BUSINESS DETAILS
|
Line of Business : |
Trader
of Pharmaceuticals, Formulations, Tablets and Capsules |
|
|
|
|
Imports from : |
China |
|
|
|
|
Terms : |
|
|
Selling : |
Credit
(30 days) |
|
|
|
|
Purchasing : |
L/C
and Cash |
GENERAL
INFORMATION
|
Customers : |
End
Users and MNCs |
|
|
|
|
No. of Employees : |
10 |
|
|
|
|
Bankers : |
Standard
Chartered Bank, Mumbai Branch |
|
|
|
|
Facilities : |
Cash
Credit : Rs.20.000 millions |
|
|
|
|
Banking Relations : |
Satisfactory |
|
|
|
|
Auditors : |
Kirit
Salagia & Company Chartered
Accountants, Mumbai |
|
|
|
|
Associates/Subsidiaries : |
Divs
Biotech Address
: 25, Kavi Nirav Lane, 3rd Floor, Zhaveri Bazar, Mumbai-400002,
Maharashtra, India Line
of Business : Traders of Chemicals |
CAPITAL STRUCTURE
|
Capital
Investment : |
|
|
Owned : |
12.500
millions |
|
Borrowed : |
20.000
millions |
|
Total : |
32.500
millions |
FINANCIAL DATA
[all figures are in Rupees
Millions]
|
Particulars |
|
31.03.2006 |
31.03.2005 |
|
Sales Turnover |
|
250.000 |
180.000 |
Expected
Sales (March 2007) : 300.000 millions
LOCAL AGENCY
FURTHER INFORMATION
Trade References :
- Mr. Chawla, Dream Unibios
Laboratories Limited, Sakinaka, Andheri (East), Mumbai-400069
- Mr. Shah, Eastern Chemicals,
Andheri (East), Mumbai
- Mr. Medipharma Drug House,
Princess Street, Mumbai-400002
Website Details :
Subject (Established 1982), is integral part of Bhawanishankar Group of
Enterprises whose motto is "Beat the Competition". Their group is
involved in Pharmaceuticals, Chemicals, Textiles and Auxiliaries, and Petroleum
business since last many decades and has been achieving new heights with every
passing year in the pharmaceutical industry.
Mr. Pradip Lohia, Founder Proprietor, Bhawanishankar Company,
diversified group activity and started trading activity of several indigenously
most required bulk drugs.
To consistently provide cost-effective high quality medicines, the
company started manufacturing operations of anti-malarial drugs, their
formulations as well as that of other sophisticated molecules. Their bulk drug
plant is located at Nadiad, in the southern part of Gujarat state and
formulations at Palghar, in western part of Maharashtra state.
With WHO & GMP certificates approved to the formulations unit, the
company has always aimed at improvement of human health care through
environmentally safe technological safe products.
Over 75 people who include over 20 professionals from diverse background
guide production of medicine for various industries producing products which
are environmentally safe technological products which meet the bio-security
needs of the customer and confirm to USP, FIB, BP, JP, IP, FCC norms etc.
Quality must be built into a drug during manufacturing. Based on this
paradigm their quality assurance and production teams work with documented
(SOP'S) validated manufacturing processes and analytical procedures to produce,
consistently high quality product and active ingredients.
They have improvised the technology by constant R & D in the recent
past for better productivity, cost and quality. Their aim is not only to give
simple IP grade product but also to arrive at 'zero-erro' level.
At Bhawanishankar Company, they work continuously to build an enduring
relationship with customers, suppliers and joint co-ordinated efforts enable
maximum customer satisfaction. The interactive engagement of all human
resources is a must in this company. This naturally challenges them intectually
and professionally inspiring them to make a difference through industry leadership
in such a dynamic and challenging environment.
The forces of change being everywhere, with intensified competition,
customer consolidation and supplier concentration programs are regularly held,
so that the team is ready with emerging communication technologies to meet the
challenges of the future.
They understand requirements of customers and suppliers more than any
other business, rivals. Following right principles and value in the past, they
have laid the firm foundation for tomorrow. They have came a long way and are
sure to touch new heights in the time to come which are pregnant with many new
ideas and hope to achieve new milestones.
Continous Upgradation of Technology through R & D
Ecological Consideration
Value for money to customers
Human face at Industrial units for safety of Manpower
Application
Specialists
The sum total of market knowledge acquired and 2 decades of being
proactive and contributing through intelligent efforts has added to the
vitality and growth of their company. Providing context-specific answers to
problems, providing innovative solutions, has led them to operate the company
in a continuous dynamic environment, by attracting customers from India and
abroad and providing specialized application oriented products.
Their Mission
"To truly be a pharmaceutical manufacturer, by providing products
that add value and enhance the quality of life."
Their Vision
The company started with trading of few products way back in 1982.
Expanding its range and slowly evolve in to quality products that meet
diversified needs of the world community.
Their Goals
Their Goals is to become a world class pharmaceutical company and create
innovative medicines for human health care, animal nutrition.
Their Values
At Bhawanishankar Company, they work continuously to build an enduring
relationship with customers, suppliers and joint co-ordinated efforts enable
maximum customer satisfaction by providing "tailor-made" products
& services.
Products
(Ammonium, Methyl, Potassium, Na) Iodide
(Calcium, Magnesium, Zinc) Stearate
(Silver, Thymol, Trimethyl Sulpho) Iodide
Albendazole
Allylestrenol
Alpha Beta Arteether
Alpha Lipoic Acid
Ambroxol Hcl
Amikacin Sulphate
Amlodipine Besylate/Plain
Amodiaquine Base/Hcl
Amodiaquine Hcl
Amoxycillin Trihydrate
Ampicillin Trihydrate /Anhydrous
Analgin
Androstanolone
Aripiprazole
Arteether
Artemether
Artemotil
Artesunate
Atenolol
Atorvastatine
Atropine Sulphate
Azithromycin
Beclomethasone Dipropionate
Betamethasone Dipropionate
Betamethasone Na Phospahte
Betamethasone Valerate
Bromhexine Hcl
Balsalazide
Carboxymethyl Cellulose (Cmc) All Garade
Carvedilol
Cefaclor Monhydrate
Cefadroxil Monohydrate
Cefixime Trihydrate
Cefoperazone Na Sterile
Ceftazidime
Ceftriaxone Sterile
Cefuroxime Axetil Crystalline
Cefuroxime Na Sterile
Cephalexin Monohydrate
Cetrizine Hcl
Chloezoxazone
Chlor Pheniramine Maleate (Cpm)
Chloramphenicol Powder/Palmitate
Chloroquine Phosphate
Chlorpromazine Hcl
Chlorthalidone
Cilostazole
Ciprofloxacin Base/Hcl
Citalopram Bhr
Clavunate Potassium Sterile (Oral/Sterile)
Clobetasole Butyrate
Clobetasole Propionate
Clopidogril Bisulpahte/ Hydro.Sul.
Cloxacillin Sodium
D-Biotin Pure
Danazol
Desloratidine
Dexamethasone Plain/Sodium
Diclofenac Sodium
Dicloxacillin Sodium
Dihydroartemisinine
Diphenhydramine Hcl
Docetaxel
Doxycycline Hcl
Erythromycin & Its Salts
Erythromycin 9-A Oxime Base
Estradiol Valerate Bp
Ethambutol
Ethinylestradiol Bp
Ethisterol Acetate
Fexofenadine Hcl
Firmenich Flavours
Flucloxacillin Sodium
Fluconazole
Flumethasone
Fluoxitine Hcl
Fluticasone Propionate
Freusamide (Under R/D)
Gatifloxacin
Gentamycin Sulphate
Glibenclamide
Glimepiride
Glycerine
Hpmc Phthalate
Hydrochlorothiazide
Hydrocortisone Acetate
Hydrocortisone Hydrogen Succinate
Hydrocortisone Na Succinate Ster.5%
Hydroxy Chloroquine Sulphate
Ibuprofen
Iso Propyl Alchohol (Ipa)
Ivermectin
Lactose
Levofloxacin Hemihydrate
Lignocaine Plain/ Hcl
Loratidine
Losartan Potassium
Meloxicam
Magesterol Acetate
Medroxy Progesterone
Methyl Iso Butyl Ketone (Mibk)
Methyl Testosterone
Methylene Chloride (Mdc)
Methylpredni Acetate
Methylpredni Hydro. Succinate
Methylpredni Na Succinate Ster.3%
Metoclopramide Hcl
Metoprolol Succinate
Metoprolol Tartrate
Metronidazole
Microcrystalline Cellulose (Mcc) All Grade
Mometasone Furate
Mometasone Monohydrate
Morantel Citrate
Nimesulide
Nabumetone
N-Amyl Meta Cresol
Nandralone
Norethisterone Acetate Bp
Norfloxacin
Ofloxacin
Omeprazole
Oxacillin Sodium
Oxaliplatin
Oxantel Pamoate
Oxytetacycline Hcl
Paclitaxel
Paracetamol
Paroxetine Hcl
Pentoprazole
Pentoxifylline
Perindopril
Piracitam
Piroxicam
Povidone Iodine
Praziquantel
Prednisolone Acetate
Prednisolone Acetate Sterile
Primaquine Phosphate
Probenecid
Propranolol Hcl
Propyle Glycol
Pvpk30
Pyrantel Pamoate
Pyrazinamide
Quinine & Its Salts
Roxithromycin
Sorbitol
Sulbactum Sodium
Tazobactum Na + Piperacillin (1:8) Sterile
Tetracycline
Theophylline
Tinidazole
Trimethyl Salyliodide
Triclabendazole
Testosterone Cypionate
Testosterone Decanonate
Testosterone Enanthate
Testosterone Enanthate Benzhydrazone
Testosterone Phenyl Propionate
Xanthan Gum (All Grade)
17-A Hydroxy Progesterone Caproate Bp
FORMULATIONS
TABLETS
Asprin 300/500
Cimetidine 200 / 400
Cotrimoxazole 480 / 960
Chloroquin 250
Primaquin 7.5 mg / 15 mg
Ciprofloxacin 250 / 500
Paracetamol 500
Paracetamol + Caffeine
lbuprofen 200 / 400
lbuprofen + Paracetamol + Caffeine
Phenylbutadine 100 mg
Cyproheptadine 4 mg
Metronidazole 200 / 400
Salbutamol 2 mg / 4 mg
Sulphadoxine + Pyrimethamine
Diclofenac Sodium 25 mg / 05 mg
Multivitamin
Vitamin B Complex
Isoniazide 100 / 300
Ethambutol 200/ 400 / 600 / 800
Pyrazinamide 500 / 700
Erythromycin Stearate 250 / 500
Mebendazole 100 mg
Ranitidine 150 / 300
CAPSULES
Ampicillin 250 / 500
Amoxycillin 250 / 500
Caephalexin 250 / 500
Doxycycilline 100
Tetracycline 250 / 500
Ampicloxa 500
Piroxicam 500
Omeprazole
CMT REPORT [Corruption, Money
laundering & Terrorism]
The Public
Notice information has been collected from various sources including but not
limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION
ON DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court
Declaration :
No records exist to suggest that subject is or was the subject of any
formal or informal allegations, prosecutions or other official proceeding for making
any prohibited payments or other improper payments to government officials for
engaging in prohibited transactions or with designated parties.
3] Asset
Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record
on Financial Crime :
Charges or conviction registered
against subject: None
5] Records
on Violation of Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records
on Int’l Anti-Money Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal
Records
No
available information exist that suggest that subject or any of its principals have
been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation
with Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation
Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA
INFORM as part of its Due Diligence do provide comments on Corporate Governance
to identify management and governance. These factors often have been predictive
and in some cases have created vulnerabilities to credit deterioration.
Our
Governance Assessment focuses principally on the interactions between a
company’s management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject
is not known to have contravened any existing local laws, regulations or
policies that prohibit, restrict or otherwise affect the terms and conditions
that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US
Dollar |
1 |
Rs.44.42 |
|
UK
Pound |
1 |
Rs.85.79 |
|
Euro |
1 |
Rs.57.80 |
SCORE &
RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
54 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit
history (10%) Market
trend (10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base
with the strongest capability for timely payment of interest and principal
sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong) capability
for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome financial
difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|